Arrow Therapeutics

What Arrow Therapeutics does

Arrow Therapeutics Ltd. is a UK-based, privately held pharmaceutical research company founded in 1998 and headquartered in London. It operates exclusively as a development-stage anti-infective drug discovery organisation, with 101-250 employees dedicated to its research mission.

The company's pipeline is concentrated in two therapeutic pillars. The first is antiviral drug discovery, with early-stage programs targeting Respiratory Syncytial Virus (RSV) and Hepatitis C — both indications that have historically attracted significant pharma interest due to high unmet need and large patient populations. The second pillar is the research and development of broad-spectrum antibiotics, addressing bacterial infections where broad-spectrum intervention is required. No product has been commercialised; all assets remain at the research or development stage.

The company's business model is pre-commercial R&D, dependent on equity capital rather than product revenue. Between 1999 and 2003, Arrow Therapeutics raised approximately $64M across four venture rounds led by Gimv and Atlas Venture, with a syndicate including 3i Group, Alta Partners, NIF Ventures, NVM Private Equity, and TVM Capital. There are no disclosed partnerships, licensing deals, customers, pricing models, or distribution channels in the source data, consistent with a pre-commercial biotech whose go-to-market will ultimately depend on either out-licensing clinical assets, partnering with a larger pharma, or a future trade sale.

Name

Arrow Therapeutics

Legal name

Arrow Therapeutics Ltd.

Website

https://arrowt.co.uk

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Arrow Therapeutics is a UK-based, development-stage pharmaceutical company founded in 1998 that discovers novel anti-infective drugs targeting Respiratory Syncytial Virus, Hepatitis C, and bacterial infections requiring broad-spectrum antibiotic intervention. It is pre-revenue with no commercialised products.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

Arrow Therapeutics Ltd. is a UK-based pharmaceutical discovery company that develops novel anti-infective drug candidates. Its research portfolio centers on antiviral therapies targeting Respiratory Syncytial Virus (RSV) and Hepatitis C, alongside broad-spectrum antibiotics for bacterial infections. All programs are pre-commercial and are in the research and development stage.

Product overview

Arrow Therapeutics Ltd. is a UK-based life sciences company operating as a development-stage research organization. The company focuses on two primary therapeutic areas: antiviral drugs targeting Respiratory Syncytial Virus (RSV) and Hepatitis C, as well as broad-spectrum antibiotics. All programs are currently in the research and development stage with no commercialized products.

Differentiator

Problem solved

Functional benefit

Products and services

• Antiviral Research Programs Early-stage antiviral drug research programs targeting Respiratory Syncytial Virus (RSV) and Hepatitis C, aimed at developing novel antiviral therapies for these viral infections. The programs are intended for pharmaceutical partners or future commercialization.
• Broad-Spectrum Antibiotics Research Research and development of broad-spectrum antibiotics targeting bacterial infections, intended to address resistance and limited treatment options. Currently in the development stage with no commercialized product.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights2 records

Direct peers

• Vir Biotechnology: Clinical-stage immunology company with a meaningful focus on infectious disease, including RSV and hepatitis programs. Most directly comparable to Arrow in therapeutic-area focus and development-stage profile.
• ReViral: UK-based clinical-stage biotech focused exclusively on developing antivirals for RSV, including both fusion inhibitors and other mechanisms. Closest like-for-like peer for Arrow's RSV antiviral work.
• Spero Therapeutics: Clinical-stage anti-infective company with a pipeline concentrated in novel antibiotics for drug-resistant bacterial infections. Directly comparable to Arrow's broad-spectrum antibiotic focus.
• Arbutus Biopharma: Hepatitis B-focused biopharma developing antiviral modalities aimed at functional cure. Comparable to Arrow's HepC antiviral program in disease area, modality focus, and small-cap development-stage profile.

Broad incumbents

• Moderna: Major biopharma with an approved RSV vaccine (mResvia) and broader infectious-disease pipeline. Comparable as a large incumbent validating the RSV therapeutic area where Arrow is developing antivirals.
• Pfizer: Global biopharma with the approved RSV vaccine Abrysvo and a longstanding anti-infective portfolio. Relevant incumbent defining commercial benchmarks for any successful Arrow RSV or antibiotic asset.
• Gilead Sciences: Global biopharmaceutical leader whose hepatitis C franchise (Sovaldi, Harvoni, Epclusa) effectively defines the standard-of-care that Arrow's HepC program must differentiate against. Relevant as the dominant incumbent shaping market dynamics.

Emerging players

• Enanta Pharmaceuticals: Small-cap biotech developing direct-acting antivirals, notably in hepatitis B and hepatitis C. Comparable in therapeutic focus and small-molecule antiviral approach, though with different stage and capital profile.
• Paratek Pharmaceuticals: Specialty biopharma focused on antibiotic innovation, including tetracycline-class agents for serious community-acquired infections. Closest specialty antibiotic peer for Arrow's broad-spectrum antibiotic program.
• Assembly Biosciences: Clinical-stage biotech developing antivirals for chronic hepatitis B and other viral diseases. Comparable in disease-area focus and development-stage profile to Arrow's HepC antiviral program.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrow Therapeutics